The Memo: Marine Biomedical Turning Mother of Pearl Into the Next Generation of Bone Grafts

Under the direction of CEO Rolee Kumar, Marine Biomedical is advancing a novel approach to bone regeneration by transforming mother of pearl from Western Australia’s pearling industry into a biomaterial designed to support natural bone healing. Built on research originating at the University of Western Australia, the company has developed PearlBone™, a marine-derived bone graft substitute that combines the consistency and scalability of manufactured materials with the biological architecture found in nature. With an FDA 510(k) submission under review, a planned clinical trial on the horizon, and manufacturing operations established in Broome, Marine Biomedical is working to bring an entirely new category of regenerative biomaterials to orthopedic surgeons.

Origin Story

Marine Biomedical’s roots can be traced back to the University of Western Australia and the work of regenerative medicine pioneer Professor Ming Hao Zheng, who recently received the Member of the Order of Australia for his contributions to the field. Alongside orthopedic surgeon Dr. Rui (Chris) Ruan, Zheng began exploring a deceptively simple question: Could nature provide a better blueprint for bone repair?

The answer emerged from an unlikely source.

Located in Western Australia, the company sits within one of the world’s most renowned pearling regions. For generations, the industry has harvested some of the world’s highest-quality pearls. Yet the oyster shells that house those pearls remained an underutilized byproduct.

“They came together, and the idea was, why don’t we look at nature to solve the problem with bone grafts?” Kumar explained. “They looked at the architecture of a pearl shell, and it mimics a lot of what natural bone does.”

The founders discovered that nacre, also known as mother of pearl, shares structural characteristics with human trabecular bone. After millions of years of natural evolution, the material had developed a complex architecture that appeared uniquely suited to supporting bone regeneration.

That concept eventually led to the formation of Marine Biomedical in 2021 and the development of PearlBone, the company’s platform technology built around marine-derived regenerative biomaterials.

The Current Landscape

The global bone grafts and bone graft substitutes market is estimated at approximately US$3–4 billion today and is projected to exceed US$5.5–6.0 billion by 2032–2033, driven by increasing fracture rates, aging populations, spinal fusion procedures, and demand for advanced regenerative biomaterials.

Yet existing solutions come with significant tradeoffs.

Autografts, which use the patient’s own bone, remain the clinical gold standard. However, harvesting that material requires a second surgical site, increasing procedure complexity, recovery burden, and surgical time.

“You are actually increasing the burden of recovery for the patient because you’re creating another site of injury,” Kumar said.

Alternatives such as allografts and xenografts can avoid that additional surgery, but they introduce challenges related to supply, variability, cost, and patient acceptance.

As a result, many companies have focused on synthetic bone graft materials that offer manufacturing consistency and reliable supply chains. The challenge is that these products often struggle to match the biological performance of natural bone.

“This is the opportunity that PearlBone is trying to capture,” Kumar said. “You’re kind of marrying the worlds of being able to produce something and have the consistency of supply and manufacturing it, but also being able to marry it up with a biological performance.”

The need is only expected to grow. Aging populations, increasing rates of osteoporosis, and rising demand for orthopedic procedures continue to drive interest in new approaches to bone regeneration.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-marine-biomedical-turning-mother-of-pearl-into-the-next-generation-of-bone-grafts

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more